• Investors may be wondering whether Cencora, at around US$310, is still fairly priced after a strong run in recent years, or whether the value case is starting to look stretched.
• The stock has recently seen a 4.0% decline over the past week and is 0.7% lower over the last 30 days, although it shows returns of 8.6% over 1 year, 90.9% over 3 years, and 164.2% over 5 years.
• Recent coverage has focused on Cencora's role in healthcare distribution and broader sector trends that keep attention on companies involved in critical drug and medical supply chains. This context helps explain why the stock can experience short term pullbacks while still attracting longer term interest.
• Cencora currently has a value score of 3 out of 6. This score comes from passing half of the standard undervaluation checks and sets the stage for comparing different valuation methods before considering a more complete way to think about value later in the article.

Approach 1: Cencora Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today using a required return. It is essentially asking what those future dollars are worth in today’s terms.

For Cencora, the 2 Stage Free Cash Flow to Equity model starts with last twelve month free cash flow of about $3.69b. Analyst projections and subsequent extrapolations extend out ten years, with forecast free cash flow reaching about $5.82b by 2035. Simply Wall St uses analyst estimates where available, then continues the series using its own growth assumptions to fill the later years.

Discounting these projected cash flows back to today results in an estimated intrinsic value of about $607.08 per share. Against a current share price of roughly $310, the model implies Cencora trades at about a 48.9% discount to this DCF estimate. On this measure alone, the shares appear materially undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Cencora is undervalued by 48.9%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: Cencora Price vs Earnings

For profitable companies, the P/E ratio is a useful way to link what you pay for the stock to the earnings the business is currently generating. It gives you a quick sense of how many dollars investors are willing to pay today for each dollar of earnings.

A higher or lower P/E often reflects what the market expects for future growth and how risky those earnings might be. Stronger expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually points to a lower, more conservative range.

Cencora currently trades on a P/E of about 37.1x, compared with the Healthcare industry average of about 24.6x and a peer average of roughly 22.3x. Simply Wall St also calculates a proprietary “Fair Ratio” of 33.5x, which estimates what Cencora’s P/E might be given factors such as its earnings growth profile, profit margins, industry, market cap and risk characteristics. This Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for those company specific features rather than treating all Healthcare stocks alike. On this basis, Cencora’s actual P/E sits above the Fair Ratio, which points to the shares screening as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Cencora Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives take your view of Cencora’s story, link it to a forecast for revenue, earnings and margins, then translate that into a Fair Value that you can compare with today’s price. All of this happens within an easy tool on Simply Wall St’s Community page that updates as news or earnings arrive. This is why one investor might build a Narrative that lines up with the most optimistic analyst fair value of about US$447, while another might lean closer to the more cautious US$340 view based on different expectations for digital investments, specialty drug demand, regulation and margins. This can help each investor decide for themselves whether the current price looks attractive, fully valued or expensive.

Do you think there's more to the story for Cencora? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.